Frontlight ResearchEarly access
WithdrawnNo phase
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis
Key facts
- Who runs it
- Dartmouth-Hitchcock Medical Center
- Where
- Lebanon, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 31 Mar 2022
- Ended
- Dec 2023
- Type of study
- Interventional
- Treatments tested
- Fibroscan
- Record updated
- 13 July 2023
- Why it stopped
- No participants enrolled
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Men and women ≥ 18 with CF and one of the following:; Normal OGTT; Elevated OGTT; Known CFRD
Who cannot take part
- Men and women without CF
Where in United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
About the trial
What the trial wants to find out
This study proposes to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis.
The group in the trial
- FibroscanOther group
One study visit for fibroscan measurement of the liver.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 July 2023